Skip to main content

Volume 18 Supplement 1

19th Annual SCMR Scientific Sessions

Sarcoidosis: comprehensive CMR evaluation and major adverse cardiac events

Background

Sarcoidosis is an idiopathic granulomatous disease that can affect any organ system, including the heart. We examined the predictive relationship of CMR imaging and clinical parameters with major adverse cardiac events (MACE) in patients with sarcoidosis.

Methods

A consecutive series of 93 study subjects undergoing clinical CMR for evaluation of cardiac sarcoidosis from 2002 to 2012 were identified from the CMR reporting database. All studies were performed using a 1.5T CMR system (Philips Achieva). Anatomic, functional and late gadolinium enhanced (LGE) images were acquired and analyzed according to standard clinical protocols. Clinical data were derived from the medical record. Vital status was confirmed using medical record and the Social Security Administration Death Master File. MACE was defined as mortality, ventricular arrhythmia, or device placement. Relationship to MACE was evaluated using proportional hazards regression.

Results

The cohort characteristics are shown in the table. Evidence of extracardiac sarcoidosis was present in 81(87%) and proven by biopsy in 39(42%). MACE occurred in 28(30%); 7(8%) died, 16(17%) had ventricular arrhythmia, and 11 (12%) underwent device placement. Analysis results are shown in the Table, including elements of the Japanese Ministry of Health guidelines for diagnosis of cardiac sarcoidosis revised in 2006 and imaging measurements. CMR measures associated with MACE include left and right atrial size, and left ventricular cavity size, mass, and function. LGE had a borderline association with MACE but was not associated with mortality. Study subjects who received steroid therapy had a reduction in MACE that was borderline significant but with no apparent reduction in mortality.

Conclusions

In this cohort of consecutive patients with sarcoidosis referred for CMR, measures of left and right atrial size, and left ventricular size, mass and function were highly predictive of both MACE and mortality. LGE was borderline associated with MACE but not predictive of mortality. Steroid therapy had a trend toward reduction of MACE but no influence on mortality. These data support the role of CMR in the routine evaluation of all patients with suspected cardiac sarcoidosis.

Table 1 Characteristics of the study cohort and associations with adverse cardiac events and mortality

Author information

Authors and Affiliations

Authors

Rights and permissions

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.

The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Higgins, A.Y., Chen, S., Manning, W.J. et al. Sarcoidosis: comprehensive CMR evaluation and major adverse cardiac events. J Cardiovasc Magn Reson 18, O101 (2016). https://doi.org/10.1186/1532-429X-18-S1-O101

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/1532-429X-18-S1-O101

Keywords

  • Sarcoidosis
  • Ventricular Arrhythmia
  • Major Adverse Cardiac Event
  • Cardiac Sarcoidosis
  • Atrial Size